Findings

What do systematic reviews say?

3 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 100%Moderate 0 · 0%High 0 · 0%

Mometasone/formoterol (MF/F) vs placebo

Adverse events at study endpoint · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse event—any—400/103 Duration of six months compared with placebo (low certainty).

2 findings from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 0.98 [0.75, 1.3]
890 participants
Low
Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 0.82 [0.62, 1.09]
894 participants
Low

Mometasone/formoterol (MF/F) vs placebo

Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 1.09 [0.66, 1.79]
890 participants
Low

Mometasone/formoterol (MF/F) vs placebo

Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 0.71 [0.41, 1.23]
894 participants
Low